Browsing: ZanidatamabBased

Survivors

FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Gastric Cancers

By NewsCancerAugust 25, 20260

The FDA has approved zanidatamab-hrii (Ziihera) in 2 indications:1in combination with tislelizumab-jsgr (Tevimbra) and fluoropyrimidine- and platinum-containing chemotherapy for the…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Chris Hoy: men must understand their prostate cancer risk

Managing Radiation Necrosis Is Next Frontier in Stereotactic Radiosurgery

FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Gastric Cancers

Browsing: ZanidatamabBased

FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Gastric Cancers

Chris Hoy: men must understand their prostate cancer risk

Managing Radiation Necrosis Is Next Frontier in Stereotactic Radiosurgery

FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Gastric Cancers

Enfortumab Vedotin Combo Shows Real-World Benefit in Urothelial Carcinoma

Chris Hoy: men must understand their prostate cancer risk

Managing Radiation Necrosis Is Next Frontier in Stereotactic Radiosurgery

FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Gastric Cancers

Enfortumab Vedotin Combo Shows Real-World Benefit in Urothelial Carcinoma

Latest Post

Chris Hoy: men must understand their prostate cancer risk

Managing Radiation Necrosis Is Next Frontier in Stereotactic Radiosurgery

FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Gastric Cancers

Subscribe to Updates

What's Hot

Browsing: ZanidatamabBased